XML 64 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Equity Incentive Plan (Tables) - Groop Internet Platform Inc [Member]
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Summary of Stock Option Activity
A summary of the Company’s stock option activity to employees, directors and service providers and related information is as follows:
 
   
Three months ended March 31, 2021
 
   
Number of
options
  
Weighted
average
exercise
price
   
Weighted
average
remaining
contractual
term
(in years)
   
Aggregate
intrinsic value
 
Outstanding at the beginning of the period
   18,097,815   0.80    6.76    134,094 
Granted
   743,156   8.21     
Exercised
   (603,914  1.32     
Forfeited
   (45,537  1.33     
  
 
 
  
 
 
   
 
 
   
 
 
 
Outstanding at the end of the period
   18,191,520   1.08    6.57    178,736 
  
 
 
  
 
 
   
 
 
   
 
 
 
Exercisable at the end of the period
   11,847,077   0.56    5.40    122,569 
  
 
 
  
 
 
   
 
 
   
 
 
 
A summary of the Company’s stock option activity to employees, directors and service providers and related information is as follows:
 
   
Year ended December 31, 2020
 
   
Number of
options
   
Weighted
average
exercise
price
   
Weighted
average
remaining
contractual
term
(in years)
   
Aggregate
intrinsic value
 
Outstanding at beginning of year
   13,841,065    0.61    7.37    10,655 
Granted
   5,152,687    1.37     
Exercised
   (167,315   0.56     
Forfeited
   (728,622   1.22     
  
 
 
   
 
 
   
 
 
   
 
 
 
Outstanding at end of year
   18,097,815    0.80    6.76    134,094 
  
 
 
   
 
 
   
 
 
   
 
 
 
Exercisable at end of year
   11,161,876    0.52    5.51    85,856 
  
 
 
   
 
 
   
 
 
   
 
 
 
Summary of Stock-based Compensation Expense
The following table sets forth the total stock-based compensation expense included in the respective components of operating expenses in the consolidated statements of comprehensive loss:
 
   
Three months
ended

March 31,
 
   
2021
   
2020
 
Research and development
  $172   $29 
Clinical Operations
   71    4 
Sales and Marketing
   877    165 
General and administrative
   393    203 
  
 
 
   
 
 
 
Total stock-based compensation expense
  $1,513   $401 
  
 
 
   
 
 
 
The following table sets forth the total stock-based compensation expense included in the respective components of operating expenses in the consolidated statements of comprehensive loss:
 
   
Year ended

December 31,
 
   
2020
   
2019
 
Research and development
  $229   $768 
Clinical Operations
   102    401 
Sales and Marketing
   1,568    182 
General and administrative
   1,078    2,053 
  
 
 
   
 
 
 
Total stock-based compensation expense
  $2,977   $3,404